Transforming Nanomedicines from Lab Scale Production to Novel Clinical Modality

Bioconjugate Chemistry

Volumn 27, Issue 4, 2016, Pages 855-862

  Landesman Milo, Dalit ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG DELIVERY; NANOPARTICLES; PHYSIOLOGY; TUMORS;

ANTICANCER DRUG; CANCER THERAPY; CLINICAL TRIAL; DRUG CARRIER; MULTI-DISCIPLINARY APPROACH; NANOCARRIERS; NANODRUGS; SMALL MOLECULES; TUMOR BIOLOGY; TUMOR PHYSIOLOGY;

ONCOLOGY;

ANTINEOPLASTIC AGENT; LIPOSOME; NANOCARRIER; DRUG CARRIER;

ANIMAL MODEL; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER STEM CELL; CANCER THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; GENOMICS; GOOD MANUFACTURING PRACTICE; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; METABOLOMICS; MOLECULAR STABILITY; MONOTHERAPY; NANOMEDICINE; NONHUMAN; PROTEOMICS; REVIEW; SCALE UP; TRANSCRIPTOMICS; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; ANIMAL; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 84965069491     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00607     Document Type: Review

References (67)

1. Hu, C. M., Aryal, S., and Zhang, L. (2010) Nanoparticle-assisted combination therapies for effective cancer treatment Ther. Delivery 1, 323-34 10.4155/tde.10.13
2. Liboiron, B. D. and Mayer, L. D. (2014) Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy Ther. Delivery 5, 149-71 10.4155/tde.13.149
3. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., and Langer, R. (2007) Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2, 751-60 10.1038/nnano.2007.387
4. Rosenblum, D. and Peer, D. (2014) Omics-based nanomedicine: the future of personalized oncology Cancer Lett. 352, 126-36 10.1016/j.canlet.2013.07.029
5. Mura, S., Bui, D. T., Couvreur, P., and Nicolas, J. (2015) Lipid prodrug nanocarriers in cancer therapy J. Controlled Release 208, 25-41 10.1016/j.jconrel.2015.01.021
6. Lila, A. S., Kiwada, H., and Ishida, T. (2014) Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin Biol. Pharm. Bull. 37, 206-11 10.1248/bpb.b13-00540
7. Yu, M., Guo, F., Tan, F., and Li, N. (2015) Dual-targeting nanocarrier system based on thermosensitive liposomes and gold nanorods for cancer thermo-chemotherapy J. Controlled Release 215, 91-100 10.1016/j.jconrel.2015.08.003
8. Zalba, S., Contreras, A. M., Haeri, A., Ten Hagen, T. L., Navarro, I., Koning, G., and Garrido, M. J. (2015) Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer J. Controlled Release 210, 26-38 10.1016/j.jconrel.2015.05.271
9. Peer, D. and Margalit, R. (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models Neoplasia 6, 343-53 10.1593/neo.03460
10. Miettinen, M. and Lasota, J. (2005) KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation Appl. Immunohistochem. Mol. Morphol. 13, 205-20 10.1097/01.pai.0000173054.83414.22
11. Karlsson, M., Nilsson, O., Thorn, M., and Winqvist, O. (2008) Detection of metastatic colon cancer cells in sentinel nodes by flow cytometry J. Immunol. Methods 334, 122-33 10.1016/j.jim.2008.02.008
12. Patriarca, C., Macchi, R. M., Marschner, A. K., and Mellstedt, H. (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review Cancer Treat. Rev. 38, 68-75 10.1016/j.ctrv.2011.04.002
13. Daka, A. and Peer, D. (2012) RNAi-based nanomedicines for targeted personalized therapy Adv. Drug Delivery Rev. 64, 1508-21 10.1016/j.addr.2012.08.014
14. Patch, A. M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., and Bailey, P. J. et al. 2015, Whole-genome characterization of chemoresistant ovarian cancer Nature 521, 489-94 10.1038/nature14410
15. Chang, D. K., Li, P. C., Lu, R. M., Jane, W. N., and Wu, H. C. (2013) Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models PLoS One 8, e83239 10.1371/journal.pone.0083239
16. Mohanty, R. K., Thennarasu, S., and Mandal, A. B. (2014) Resveratrol stabilized gold nanoparticles enable surface loading of doxorubicin and anticancer activity Colloids Surf., B 114, 138-43 10.1016/j.colsurfb.2013.09.057
17. Peer, D., Park, E. J., Morishita, Y., Carman, C. V., and Shimaoka, M. (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target Science 319, 627-30 10.1126/science.1149859
18. Andriyanov, A. V., Koren, E., Barenholz, Y., and Goldberg, S. N. (2014) Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes PLoS One 9, e92555 10.1371/journal.pone.0092555
19. Li, Z. Y., Liu, Y., Wang, X. Q., Liu, L. H., Hu, J. J., Luo, G. F., Chen, W. H., Rong, L., and Zhang, X. Z. (2013) One-pot construction of functional mesoporous silica nanoparticles for the tumor-acidity-activated synergistic chemotherapy of glioblastoma ACS Appl. Mater. Interfaces 5, 7995-8001 10.1021/am402082d
20. Cohen, K., Emmanuel, R., Kisin-Finfer, E., Shabat, D., and Peer, D. (2014) Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters ACS Nano 8, 2183-95 10.1021/nn500205b
21. Mizrahy, S., Goldsmith, M., Leviatan-Ben-Arye, S., Kisin-Finfer, E., Redy, O., Srinivasan, S., Shabat, D., Godin, B., and Peer, D. (2014) Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles Nanoscale 6, 3742-52 10.1039/c3nr06102g
22. Xu, S., Wang, W., Li, X., Liu, J., Dong, A., and Deng, L. (2014) Sustained release of PTX-incorporated nanoparticles synergized by burst release of DOXHCl from thermosensitive modified PEG/PCL hydrogel to improve anti-tumor efficiency Eur. J. Pharm. Sci. 62, 267-73 10.1016/j.ejps.2014.06.002
23. Mandal, A., Krishnan, R. S., Thennarasu, S., Panigrahi, S., and Mandal, A. B. (2010) Two-dimensional surface properties of an antimicrobial hydantoin at the air-water interface: an experimental and theoretical study Colloids Surf., B 79, 136-41 10.1016/j.colsurfb.2010.03.042
24. Naskar, B., Ghosh, S., and Moulik, S. P. (2012) Solution behavior of normal and reverse triblock copolymers (pluronic L44 and 10R5) individually and in binary mixture Langmuir 28, 7134-46 10.1021/la3000729
25. Prieto Garcia, A. and Pineda de la Losa, F. (2010) Immunoglobulin E-mediated severe anaphylaxis to paclitaxel J. Invest. Allergol. Clin. Immunol. 20, 170-1
26. Wang, Y., Wu, K. C., Zhao, B. X., Zhao, X., Wang, X., Chen, S., Nie, S. F., Pan, W. S., Zhang, X., and Zhang, Q. (2011) A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety J. Biomed. Biotechnol. 2011, 1 10.1155/2011/854872
27. Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., and Zhang, H. et al. 2012, Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial J. Clin. Oncol. 30, 2055-62 10.1200/JCO.2011.39.5848
28. Kraft, J. C., Freeling, J. P., Wang, Z., and Ho, R. J. (2014) Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems J. Pharm. Sci. 103, 29-52 10.1002/jps.23773
29. Peer, D. and Lieberman, J. (2011) Special delivery: targeted therapy with small RNAs Gene Ther. 18, 1127-33 10.1038/gt.2011.56
30. Peer, D. (2012) Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles Adv. Drug Delivery Rev. 64, 1738-48 10.1016/j.addr.2012.06.013
31. Vorup-Jensen, T. and Peer, D. (2012) Nanotoxicity and the importance of being earnest Adv. Drug Delivery Rev. 64, 1661-2 10.1016/j.addr.2012.09.002
32. Peer, D. (2013) A daunting task: manipulating leukocyte function with RNAi Immunol. Rev. 253, 185-97 10.1111/imr.12044
33. Mirsky, S. Fighting Cancer with Physics (podcast) Sci. Am. 2014; http://www.scientificamerican.com/podcast/episode/rakesh-jain-fight-cancer-with-physics/
34. Araki, T., Ogawara, K., Suzuki, H., Kawai, R., Watanabe, T., Ono, T., and Higaki, K. (2015) Augmented EPR effect by photo-triggered tumor vascular treatment improved therapeutic efficacy of liposomal paclitaxel in mice bearing tumors with low permeable vasculature J. Controlled Release 200, 106-14 10.1016/j.jconrel.2014.12.038
35. Maeda, H. (2012) Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting Proc. Jpn. Acad., Ser. B 88, 53-71 10.2183/pjab.88.53
36. Zhao, Y., Alakhova, D. Y., and Kabanov, A. V. (2013) Can nanomedicines kill cancer stem cells? Adv. Drug Delivery Rev. 65, 1763-83 10.1016/j.addr.2013.09.016
37. Hansen, A. E., Petersen, A. L., Henriksen, J. R., Boerresen, B., Rasmussen, P., Elema, D. R., Rosenschold, P. M., Kristensen, A. T., Kjaer, A., and Andresen, T. L. (2015) Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes ACS Nano 9, 6985-95 10.1021/acsnano.5b01324
38. Deshpande, P. P., Biswas, S., and Torchilin, V. P. (2013) Current trends in the use of liposomes for tumor targeting Nanomedicine (London, U. K.) 8, 1509-28 10.2217/nnm.13.118
39. Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan-Halevy, I., Rosenblum, D., Goldsmith, M., Abraham, A., Benjamini, O., and Bairey, O. et al. 2016, Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies Proc. Natl. Acad. Sci. U. S. A. 113, E16 10.1073/pnas.1519273113
40. Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., and Davis, M. E. (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 104, 15549-54 10.1073/pnas.0707461104
41. Mandel, A. B. and Moulik, S. P. (1982) Interaction of CTAB and SDS in the light of precipitation, solubilization, and mixed micelle formation in electrolytes, nonelectrolytes and non-ionic detergents environments, In Solution Behavior of Surfactants-Theoretical and Applied Aspects (Mittal, K. L. and Fendler, E. J., Eds.) pp 521-541, Vol 1, Plenum Press, New York.
42. Lee, E., Enomoto, R., Suzuki, C., Ohno, M., Ohashi, T., Miyauchi, A., Tanimoto, E., Maeda, K., Hirano, H., and Yokoi, T. et al. 2007, Wogonin, a plant flavone, potentiates etoposide-induced apoptosis in cancer cells Ann. N. Y. Acad. Sci. 1095, 521-6 10.1196/annals.1397.056
43. Conde, J., Tian, F., and Artzi, N. (2015) RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment Mater. Today 10.1016/j.mattod.2015.07.005
44. Jiwpanich, S., Ryu, J. H., Bickerton, S., and Thayumanavan, S. (2010) Noncovalent encapsulation stabilities in supramolecular nanoassemblies J. Am. Chem. Soc. 132, 10683-5 10.1021/ja105059g
45. Mignani, S., Bryszewska, M., Klajnert-Maculewicz, B., Zablocka, M., and Majoral, J. P. (2015) Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report Biomacromolecules 16, 1-27 10.1021/bm501285t
46. Wong, P. K., Yu, F., Shahangian, A., Cheng, G., Sun, R., and Ho, C. M. (2008) Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm Proc. Natl. Acad. Sci. U. S. A. 105, 5105-10 10.1073/pnas.0800823105
47. Van Vlerken, L. E., Duan, Z., Little, S. R., Seiden, M. V., and Amiji, M. M. (2008) Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model Mol. Pharmaceutics 5, 516-26 10.1021/mp800030k
48. Landesman-Milo, D. and Peer, D. (2014) Toxicity profiling of several common RNAi-based nanomedicines: a comparative study Drug Delivery Transl. Res. 4, 96-103 10.1007/s13346-013-0158-7
49. Domcke, S., Sinha, R., Levine, D. A., Sander, C., and Schultz, N. (2013) Evaluating cell lines as tumour models by comparison of genomic profiles Nat. Commun. 4, 2126 10.1038/ncomms3126
50. Basel, M. T., Balivada, S., Beck, A. P., Kerrigan, M. A., Pyle, M. M., Dekkers, J. C., Wyatt, C. R., Rowland, R. R., Anderson, D. E., and Bossmann, S. H. et al. 2012, Human xenografts are not rejected in a naturally occurring immunodeficient porcine line: a human tumor model in pigs BioRes. Open Access 1, 63-8 10.1089/biores.2012.9902
51. Fu, S., Wang, J., Sun, W., Xu, Y., Zhou, X., and Cheng, W. (2014) Preclinical humanized mouse model with ectopic ovarian tissues Exp. Ther. Med. 8, 742-746 10.3892/etm.2014.1819
52. Ma, L., Kohli, M., and Smith, A. (2013) Nanoparticles for combination drug therapy ACS Nano 7, 9518-25 10.1021/nn405674m
53. Szebeni, J., Bedocs, P., Urbanics, R., Bunger, R., Rosivall, L., Toth, M., and Barenholz, Y. (2012) Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model J. Controlled Release 160, 382-7 10.1016/j.jconrel.2012.02.029
54. Dezsi, L., Fulop, T., Meszaros, T., Szenasi, G., Urbanics, R., Vazsonyi, C., Orfi, E., Rosivall, L., Nemes, R., and Kok, R. J. et al. 2014, Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses J. Controlled Release 195, 2-10 10.1016/j.jconrel.2014.08.009
55. Desai, N. P., Trieu, V., Hwang, L. Y., Wu, R., Soon-Shiong, P., and Gradishar, W. J. (2008) Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status Anti-Cancer Drugs 19, 899-909 10.1097/CAD.0b013e32830f9046
56. Liu, K. C. and Yeo, Y. (2014) Extracellular stability of nanoparticulate drug carriers Arch. Pharmacal Res. 37, 16-23 10.1007/s12272-013-0286-0
57. Gullotti, E. and Yeo, Y. (2012) Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles J. Controlled Release 164, 170-6 10.1016/j.jconrel.2012.04.042
58. Torchilin, V. P. (2014) Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery Nat. Rev. Drug Discovery 13, 813-27 10.1038/nrd4333
59. le Masne de Chermont, Q., Chaneac, C., Seguin, J., Pelle, F., Maitrejean, S., Jolivet, J. P., Gourier, D., Bessodes, M., and Scherman, D. (2007) Nanoprobes with near-infrared persistent luminescence for in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 104, 9266-71 10.1073/pnas.0702427104
60. Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., and Yeo, Y. (2013) Nanoparticle characterization: state of the art, challenges, and emerging technologies Mol. Pharmaceutics 10, 2093-110 10.1021/mp300697h
61. Chen, H., Kim, S., He, W., Wang, H., Low, P. S., Park, K., and Cheng, J. X. (2008) Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging Langmuir 24, 5213-7 10.1021/la703570m
62. Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., Gertler, F. B., and Kamm, R. D. (2012) Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function Proc. Natl. Acad. Sci. U. S. A. 109, 13515-20 10.1073/pnas.1210182109
63. Korostynska, O., Gil, E., Arshak, A., and Arshak, K. (2007) Review on State-of-the-art in Polymer Based pH Sensors Sensors 7, 3027-3042
64. Laouini, A., Limayem-Blouza, I., Sfar, S., Charcosset, C., Fessi, H., and Jaafar-Maalej, C. (2012) Preparation, Characterization and Applications of Liposomes: State of the Art J. Colloid Sci. Biotechnol. 1 (2) 147-168 10.1166/jcsb.2012.1020
65. Cohen, Z. R., Ramishetti, S., Peshes-Yaloz, N., Goldsmith, M., Wohl, A., Zibly, Z., and Peer, D. (2015) Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles ACS Nano 9, 1581-91 10.1021/nn506248s
66. Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A. G., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., and Peer, D. (2015) Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles ACS Nano 9, 6706-16 10.1021/acsnano.5b02796
67. Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., and Tam, Y. K. et al. 2012, Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA Mol. Ther. - Nucleic Acids 1, e37 10.1038/mtna.2012.28